Itaconate mimetic
Alternative Names: Itaconate mimetic - Eli Lilly and CompanyLatest Information Update: 14 Mar 2024
At a glance
- Originator Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Immunological disorders
Most Recent Events
- 20 Feb 2024 Itaconate mimetic is available for licensing as of 20 Feb 2024. https://www.lilly.com/partners/collaborate-with-us
- 20 Feb 2024 Phase-I clinical trials in Immunological disorders (unspecified route) (Eli Lilly and Company pipeline, February 2024)